BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
BLRXBioLineRx(BLRX) Prnewswire·2024-08-15 19:00
  • Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60% by end of Q4 - - Doubled the number of centers ordering APHEXDA during the second quarter - - Entered into clinical trial agreement with St. Jude Children's Research Hospital to evaluate motixafortide for hematopoietic stem cell mobilization for gene therapies in sickle cell disease - - Management to host con ...